Dogwood Therapeutics, Inc.

What they do

Dogwood Therapeutics is a development-stage biopharmaceutical company focused on treating pain and neuropathy, with lead candidate Halneuron (a Na v 1.7 modulator) in Phase 2b for chemotherapy-induced neuropathic pain (CINP) and SP16, a peptide with immunomodulatory properties, in early development for chemotherapy-induced peripheral neuropathy. The company became the sole owner of Pharmagesic and Wex Pharmaceuticals in October 2024. It has no approved products and no revenue.

Revenue drivers

• Halneuron (Na v 1.7 modulator) — Lead product candidate for CINP; no approved products, potential first FDA-approved CINP treatment; currently in Phase 2b trial with 217 patients enrolled.
• SP16 — Peptide drug for chemotherapy-induced peripheral neuropathy; Phase 1b study planned, fully funded by National Cancer Institute grant; no revenue yet.
• Legacy antiviral assets partnership — Announced a worldwide development and commercialization partnership with potential value up to $100M to Dogwood and CVR holders; details not specified in filings.

Recent performance

For Q2 2026, Dogwood reported a net loss attributable to common stockholders of $11.5 million, or $0.34 per share, compared to $3.8 million, or $1.99 per share, in Q2 2025. R&D expenses were $3.2 million (up from $2.6 million), primarily due to higher Halneuron study costs; G&A expenses were $1.6 million (up from $1.3 million). The company recorded a non-cash impairment charge of $6.7 million in the first half of 2026 due to a decline in stock price. Cash and equivalents were $9.6 million as of June 30, 2026, and management expects runway through the Q4 2026 Phase 2b readout.

Strategy

Dogwood is prioritizing completion of its Halneuron Phase 2b trial in CINP, with top-line results expected in fall 2026, and has initiated a 12-week open-label extension study. It is advancing SP16 into Phase 1 development after receiving FDA IND approval, with a fully funded study at the University of Virginia. The company is also pursuing a partnership for legacy antiviral assets with potential value up to $100M. Management aims to address the unmet need in CINP, where no FDA-approved treatments exist, and expand Halneuron into other pain indications.

Risks

• Going concern risk — The company has substantial doubt about its ability to continue as a going concern without additional capital, as stated in the 2025 10-K.
• Clinical trial failure — Halneuron's Phase 2b trial may fail to meet endpoints; interim results showed separation from placebo but no statistical significance reported.
• Cash runway — Cash of $9.6 million may not be sufficient beyond the Q4 2026 readout; additional financing will be needed.
• Regulatory and approval uncertainty — CINP has no FDA-approved treatments, and Halneuron has only fast-track designation, not approval; regulatory path is uncertain.

Outlook

Management expects top-line results from the Halneuron Phase 2b trial in fall 2026, with over 220 patients enrolled to provide 80%+ statistical power. The SP16 Phase 1b study is expected to start enrolling in the second half of 2026, fully funded by the National Cancer Institute. The company anticipates its cash position will fund operations through the readout, but additional capital will be required thereafter.